A formidable opponent
Melanoma is the most serious type of skin cancer. For patients diagnosed with high-risk forms—specifically stages IIB to IV—the danger doesn't end with surgery to remove the tumour. Even after successful resection, there's a significant chance the cancer can return,
often within the first two years. These recurrences are frequently metastatic, meaning the cancer spreads to other parts of the body, making it much harder to treat. This persistent threat has created an urgent need for new adjuvant therapies, which are treatments given after initial surgery to eliminate any remaining cancer cells and prevent the disease from coming back.
A two-punch combination
The treatment at the centre of this new trial, called INTerpath-001, is a groundbreaking combination. It pairs Merck's established immunotherapy drug, Keytruda (pembrolizumab), with an investigational, personalised mRNA vaccine from Moderna, known as intismeran autogene (or V940/mRNA-4157). Keytruda is an immune checkpoint inhibitor. In simple terms, some cancer cells can create a 'cloak of invisibility' that helps them hide from the body's immune system. Keytruda works by removing this cloak, allowing immune cells to see and attack the cancer. The vaccine then provides the second punch, giving the immune system highly specific training to hunt down the cancer cells.
A vaccine tailored for you
The most revolutionary part of this approach is the vaccine itself. It is not a one-size-fits-all shot; it is an individualized neoantigen therapy (INT). After a patient's tumour is surgically removed, scientists analyse its genetic makeup to identify its unique mutational signature. Using this 'fingerprint', they design and manufacture a custom mRNA vaccine for that specific patient. This vaccine carries instructions for up to 34 'neoantigens'—proteins that are unique to the patient's cancer cells. When injected, the patient's own cells use these mRNA instructions to produce the neoantigens, effectively showing the immune system a molecular mugshot of the enemy it needs to find and destroy throughout the body.
A pivotal moment in research
The news that the Phase 3 trial has fully enrolled its 1,137 patients is significant. But even more importantly, recent results announced on August 19, 2026, revealed that the trial has already met its primary goals. An interim analysis showed that the combination of the vaccine and Keytruda led to a 'statistically significant and clinically meaningful' improvement in recurrence-free survival compared to Keytruda alone. This means patients receiving the combination therapy remained cancer-free for longer. It also reduced the risk of the cancer spreading to distant parts of the body. This is the first time a personalised mRNA cancer therapy has delivered positive results in a large-scale Phase 3 study, a moment many experts are calling a landmark for cancer research.
The path forward
These positive results build upon earlier, highly encouraging data from a smaller Phase 2 trial. In that study's five-year follow-up, the combination treatment reduced the risk of recurrence or death by 49% compared to Keytruda alone. With the Phase 3 trial now confirming this benefit on a much larger scale, Merck and Moderna plan to present the detailed data at an upcoming medical meeting and discuss regulatory submissions with authorities worldwide. While the treatment is not yet available, this success opens the door for a potential new standard of care in treating high-risk melanoma. The companies are also exploring the use of this personalised vaccine technology in other cancers, including non-small cell lung cancer, bladder cancer, and kidney cancer.
